• head_banner_01

이황화 결합을위한 기타 보호 아미노산

짧은 설명 :

 

NO

제품

CAS NO

애플리케이션

1

FMOC-CYS (MMT) -OH

177582-21-7

이황화 결합

2

fmoc-cys (4-allylbutyrate) -oh

/

이황화 결합

3

MPA (TRT) -OH

27144-18-9

시퀀스 끝


제품 세부 사항

제품 태그

제품 세부 사항

NO

제품

CAS NO

애플리케이션

주요 품질 표시기

청정

이성질체

특정 불순물

*max1

수분

1

FMOC-CYS (ACM) -OH

86060-81-3

이황화 결합

≥99.0%

≤0.1%

≤0.1%

≤0.2%

≤1.0%

2

FMOC-CYS (MMT) -OH

177582-21-7

이황화 결합

≥98.0%

≤0.2%

≤0.3%

≤0.5%

≤1.0%

3

fmoc-cys (4-allylbutyrate) -oh

/

이황화 결합

≥98.0%

≤0.2%

≤0.3%

≤0.5%

≤1.0%

4

MPA (TRT) -OH

27144-18-9

시퀀스 끝

≥99.5%

/

≤0.1%

≤0.2%

≤1.0%

5

fmoc-thr (tbu) -ol

189337-28-8

Octreotide

≥97.0%

≤0.3%

≤0.5%

≤1.0%

≤1.0%

6

fmoc-d-arg (pbf) -oh

187618-60-6

데모 프레 신

≥99.0%

≤0.2%

≤0.3%

≤0.3%

≤2.0%

7

FMOC-GLY-GLY-OH

35665-38-4

Bivalirudin

≥99.5%

/

≤0.1%

≤0.2%

≤1.0%

8

FMOC-GLY-GLY-OH

170941-79-4

Terlipressin

≥99.5%

/

≤0.1%

≤0.2%

≤1.0%

9

FMOC-GLY-GLY-GLY-OH

/

Bivalirudin

≥99.5%

/

≤0.1%

≤0.2%

≤1.0%

10

fmoc-gly-asp (tbu) -oh

/

Bivalirudin

≥99.5%

/

≤0.15%

≤0.2%

≤1.0%

11

BOC-CYS (TRT) -OH

21947-98-8

시퀀스 끝

≥99.0%

≤0.2%

≤0.3%

≤0.3%

≤1.0%

12

BOC-ARG (PBF) -OH

200124-22-7

시퀀스 끝

≥99.0%

≤0.2%

≤0.3%

≤0.3%

≤1.0%

13

BOC-ALA-OH

15761-38-3

시퀀스 끝

≥99.0%

≤0.2%

≤0.3%

≤0.3%

≤1.0%

14

Boc-d-phe-oh

18942-49-9

시퀀스 끝

≥99.0%

≤0.2%

≤0.3%

≤0.3%

≤1.0%

15

Boc-Gly-oh

4530-20-5

시퀀스 끝

≥99.5%

/

≤0.1%

≤0.2%

≤1.0%

16

Boc-Lys (Boc) -oh.dcha

15098-69-8

시퀀스 끝

≥99.0%

≤0.2%

≤0.3%

≤0.3%

≤1.0%

17

BOC-SER (TBU) -OH

7738-22-9

시퀀스 끝

≥99.0%

≤0.2%

≤0.3%

≤0.3%

≤1.0%

18

BOC-THR (TBU) -OH

13734-40-2

시퀀스 끝

≥99.0%

≤0.2%

≤0.3%

≤0.3%

≤1.0%

19

BOC-D-ALA-OH

7764-95-6

시퀀스 끝

≥99.0%

≤0.2%

≤0.3%

≤0.3%

≤1.0%

20

Boc-Met-Oh

2488-15-5

시퀀스 끝

≥99.0%

≤0.2%

≤0.3%

≤0.3%

≤1.0%

21

BOC-TYR (TBU) -OH

47375-34-8

시퀀스 끝

≥99.0%

≤0.2%

≤0.3%

≤0.3%

≤1.0%

22

BOC-D-ARG (PDF) -OH

187618-60-6

시퀀스 끝

≥99.0%

≤0.2%

≤0.3%

≤0.3%

≤1.0%

23

boc-asp (otbu) -oh.dcha

1913/12/8

시퀀스 끝

≥99.0%

≤0.2%

≤0.3%

≤0.3%

≤1.0%

24

FMOC-HOMOARG (PBF) -OH

1159680-21-3

eptifibatide

≥98.5%

≤0.2%

/

≤0.5%

≤2.0%

25

FMOC-ASP-OTBU

129460-09-9

티말파 신

≥99.5%

≤0.1%

≤0.1%

≤0.2%

≤1.0%

26

fmoc-tyr (me) -oh

77128-72-4

카베 토신

≥98.5%

≤0.2%

≤0.3%

≤0.5%

≤1.0%

27

fmoc-nor (boc) -oh

109425-55-0

아토 시바

옴프레신

Daptomycin

≥99.5%

≤0.1%

≤0.1%

≤0.2%

≤2.0%

28

fmoc-d-tyr (et) -oh

162502-65-0

아토 시바

≥99.5%

≤0.1%

≤0.1%

≤0.2%

≤1.0%

29

fmoc-asp (oall) -oh

146982-24-3

멜라 노탄

≥99.0%

≤0.2%

≤0.3%

≤0.3%

≤1.0%

30

AC-NLE-OH

15891-49-3

멜라 노탄

≥99.0%

/

≤0.3%

≤0.3%

≤1.0%

31

FMOC-NLE-OH

77284-32-3

멜라 노탄

아파멜라노 타이드

≥99.0%

/

≤0.3%

≤0.3%

≤1.0%

32

AC-GLU (OTBU) -OH

84192-88-1

Argireline

아세틸 옥타 펩티드 -3

≥99.0%

≤0.2%

≤0.3%

≤0.3%

≤1.0%

33

AC-β-Ala-OH · DCHA

/

아세틸 테트라 펩티드 -5

≥99.0%

/

≤0.3%

≤0.3%

≤1.0%

34

fmoc-ß-ala-oh

35737-10-1

아세틸 테트라 펩티드 -5

≥99.5%

/

≤0.1%

≤0.2%

≤1.0%

35

FMOC-HYP (TBU) -OH

122996-47-8

icatibant

≥98.0%

≤0.2%

≤0.3%

≤0.5%

≤1.0%

36

FMOC-THI-OH

130309-35-2

icatibant

≥98.0%

≤0.2%

≤0.3%

≤0.5%

≤1.0%

37

FMOC-D-TIC-OH

130309-33-0

icatibant

≥98.0%

≤0.2%

≤0.3%

≤0.5%

≤1.0%

38

FMOC-OIC-OH

130309-37-4

icatibant

≥98.0%

≤0.2%

≤0.3%

≤0.5%

≤1.0%

39

Boc-sar-oh

13734-36-6

사라 라신

≥98.0%

≤0.2%

≤0.3%

≤0.5%

≤1.0%

40

FMOC-SAR-OH

77128-70-2

사라 라신

≥98.0%

≤0.2%

≤0.3%

≤0.5%

≤1.0%

41

fmoc-tyr (so3na) -oh.h2o

106864-37-3

성인

≥98.0%

≤0.2%

≤0.3%

≤0.5%

≤1.0%

42

fmoc-d-asp (otbu) -oh

112883-39-3

Daptomycin

≥98.5%

≤0.2%

≤0.3%

≤0.5%

≤1.0%

43

AC-SER (TBU) -OH

77285-09-7

아파멜라노 타이드

≥99.0%

≤0.2%

≤0.3%

≤0.3%

≤1.0%

44

Boc-Homocys (trt) -oh

201419-16-1

Depreotide

≥98.0%

≤0.2%

≤0.3%

≤0.5%

≤1.0%

45

fmoc-Homocys (trt) -oh

167015-23-8

Depreotide

≥98.0%

≤0.2%

≤0.3%

≤0.5%

≤1.0%

46

FMOC-DAB-OH

161420-87-7

뱀 독

≥99.0%

≤0.2%

≤0.3%

≤0.3%

≤1.0%

*max1 = max 미지의 순도

기타 지표 :

- 아세트산 : ≤0.02% (모든 제품)

- 에틸 아세테이트 : ≤0.5% (모든 제품)

- 알코올 : ≤0.5% (모든 제품)

-알지 못하는 불순물 : FMOC-TRP (BOC) -OH (143824-78-6) ≤0.3%; 기타 ≤0.2%


  • 이전의:
  • 다음:

  • 여기에 메시지를 작성하여 우리에게 보내십시오